Olmesartan Medoxomil Krka (Olmesartan Medoxomil)

Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑driven vasoconstriction, aldosterone release and sympathetic activation. This leads to vasodilation, reduced sodium and water retention, and a consequent decrease in systemic arterial pressure.

The dosage of Olmesartan Medoxomil Krka is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, renal function and concomitant therapies. The prescriber determines the appropriate strength and titration schedule according to approved labeling and clinical judgment.

Olmesartan medoxomil is contraindicated in the second and third trimesters of pregnancy because it can cause fetal toxicity. Limited data are available for breastfeeding; therefore, the drug should be used only if the potential benefit justifies the potential risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Olmesartan belongs to the angiotensin II receptor blocker (ARB) class, which offers blood‑pressure reduction similar to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers or diuretics, ARBs provide a distinct mechanism targeting the renin‑angiotensin system, often preferred in patients with renal impairment or those intolerant to ACE inhibitors.

Olmesartan Medoxomil Krka tablets should be stored at temperatures below 25 °C, in the original packaging, protected from moisture and direct sunlight. Do not store in areas with high humidity or extreme heat to maintain product stability.

The medication is supplied as oral tablets that are taken whole with water, usually once daily. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any specific administration considerations.

Serious adverse events include angio‑edema, severe hypotension, acute kidney injury and hyper‑kalemia, especially when combined with other drugs that affect renal function or potassium balance. Prompt medical attention is required if any signs of swelling, dizziness, or rapid decline in kidney function occur.

Patients with known hypersensitivity to olmesartan or any component of the formulation should avoid the drug. It is also contraindicated in pregnant women during the second and third trimesters and in patients with severe hepatic impairment or a history of angio‑edema related to ARB or ACE‑inhibitor therapy.